46
Participants
Start Date
July 18, 2019
Primary Completion Date
February 27, 2020
Study Completion Date
March 20, 2020
ApTOLL
ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
Placebo
100 mL 0.9% Sodium Chloride solution
Clinical Pharmacology Department. Hospital Universitario de La Princesa, Madrid
Collaborators (1)
Ministry of Science and Innovation, Spain
OTHER_GOV
Anagram
UNKNOWN
aptaTargets S.L.
INDUSTRY